NasdaqGS:SDGRHealthcare Services
Is Manas AI’s Platform Deal Reshaping the Investment Case For Schrödinger’s (SDGR) Drug Discovery Model?
In January 2026, Manas AI announced a multi-year agreement granting it extensive access to Schrödinger’s physics-based computational drug discovery platform and expert support, aimed at integrating this technology with its AI “world model” for identifying diverse molecular binders.
A key angle for investors is that Schrödinger’s tools will be tightly embedded into Manas AI’s large-scale discovery workflows, potentially reinforcing Schrödinger’s position in AI-enabled molecular design...